Our Take
Cadence is betting its survival on automation, not because it can prove AI works in clinical care, but because regulators and insurers are already questioning the low-touch monitoring model that built the company.
Why it matters
Cadence's core business—charging insurers monthly for clinician-run remote monitoring—is under federal and insurer scrutiny for potential abuse and quality concerns. The $100 million bet on AI automation signals the company sees its current model as unsustainable, not as a way to enhance what already works.
Do this week
Health system procurement teams: audit your Cadence contracts now for any cost-sharing or quality guarantees tied to clinical outcomes, not just encounter volume, before the company shifts to an AI-first model.
Cadence moves to automate its clinician workforce
Cadence, a digital health company managing remote care for over 100,000 patients with chronic conditions, raised $100 million led by Spark Capital. The funding values the company at $1.23 billion and marks a pivot toward AI automation of work performed by its hundreds of clinicians.
Cadence currently operates through a per-patient monthly fee model charged to insurers and health systems. The company monitors patients with hypertension, diabetes, and heart failure using connected devices like blood pressure cuffs, paired with clinician oversight. It has contracts with over 20 health systems and receives patient referrals through those networks.
CEO and founder Chris Altchek stated the company aims to "take it to the next level" by automating portions of clinician work. The funding explicitly positions AI as the vehicle for that expansion.
Regulatory and payer pressure is the real driver
Cadence's timing matters. The federal government's Office of Inspector General and major insurers including UnitedHealthcare have publicly questioned the reimbursement model underlying Cadence's business. Critics argue the framework is ripe for abuse and may support low-quality care by incentivizing volume over clinical outcomes.
That scrutiny has likely forced the company's hand. Rather than defending the human-clinician model as sufficient, Cadence is positioning automation as the answer to quality and sustainability concerns. The $100 million bet signals the company views its current model as vulnerable, not as a proven approach worth doubling down on through traditional growth.
The irony is sharp: Cadence is not investing in AI because it has demonstrated that AI improves outcomes in chronic disease management. It is investing because regulators and payers are questioning whether the status quo is defensible.
What health systems and insurers should watch
Two things matter for contract holders: first, the terms under which Cadence deploys AI into your patient workflows. If the company shifts from clinician-led to AI-led decision-making, clinical liability, regulatory compliance, and patient safety protocols all change. Contracts written for remote monitoring by licensed clinicians do not automatically extend to AI-assisted or AI-primary workflows.
Second, the outcome guarantees embedded in your agreements. If your contract specifies quality or cost targets tied to Cadence's clinician model, those metrics may no longer apply once automation is introduced. Renegotiation risk is high.
Cadence's $100 million bet is not evidence that AI improves chronic disease outcomes. It is evidence that the old model is under enough pressure that the company is willing to invest heavily in a different approach. That is a business inflection, not a clinical validation.